Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zattarin, Emma, Presti, Daniele, Mariani, Luigi, Sposetti, Caterina, Leporati, Rita, Menichetti, Alice, Corti, Chiara, Benvenuti, Chiara, Fucà, Giovanni, Lobefaro, Riccardo, Ligorio, Francesca, Provenzano, Leonardo, Vingiani, Andrea, Del Vecchio, Marta, Griguolo, Gaia, Sirico, Marianna, Bernocchi, Ottavia, Marra, Antonio, Zagami, Paola, Agostinetto, Elisa, Jacobs, Flavia, Di Mauro, Pierluigi, Esposito, Andrea, Giorgi, Carlo Alberto, Lalli, Luca, Boldrini, Laura, Giacchetti, Pier Paolo Berton, Schianca, Ambra Carnevale, Guarneri, Valentina, Pedersini, Rebecca, Losurdo, Agnese, Zambelli, Alberto, Generali, Daniele, Criscitiello, Carmen, Curigliano, Giuseppe, Pruneri, Giancarlo, de Braud, Filippo, Dieci, Maria Vittoria, Vernieri, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110597/
https://www.ncbi.nlm.nih.gov/pubmed/37069173
http://dx.doi.org/10.1038/s41523-023-00534-1
Descripción
Sumario:Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.

Ejemplares similares